Research Topics
Species | Noah D KauffSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?Noah D Kauff
J Clin Oncol 26:9-10. 2008
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-upNoah D Kauff
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:314-20. 2005..Limited information is available regarding the impact of this approach on either quality of life (QOL) or need for invasive follow-up in this group of women...
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective studyNoah D Kauff
Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
J Clin Oncol 26:1331-7. 2008....
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2Noah D Kauff
Gynecology Service, Department of Surgery, and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:2921-7. 2007..Considerations that may impact the appropriate timing of the procedure will be reviewed, and the potential role of RRSO in BRCA-negative hereditary breast cancer families will also be discussed...
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer familiesNoah D Kauff
Department of Gynecology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 97:1382-4. 2005..66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer...
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer familiesZsofia K Stadler
Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
Breast Cancer Res Treat 123:581-5. 2010..Major gene rearrangements involving the BRCA1 and BRCA2 genes appear to contribute little to the burden of inherited predisposition to breast and ovarian cancer in the Ashkenazim...
Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancerTomas Kirchhoff
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 96:68-70. 2004..22 to 1.14). We thus recommend that counseling for colorectal cancer screening and prevention in individuals with BRCA mutations be based on the personal and family history of colorectal cancer or associated syndromic malignancies...
BRCA mutations and risk of prostate cancer in Ashkenazi JewsTomas Kirchhoff
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:2918-21. 2004..Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study...
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinomaRobert A Soslow
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mod Pathol 25:625-36. 2012..60 (95% CI, 0.32-0.84) and a negative predictive value of 1.0 (95% CI, 0.63-1.0)). These preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas...
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutationsJaya M Satagopan
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:3776-81. 2002..To address this, we have used a case-control design that does not involve familial aggregation to estimate the lifetime penetrance of ovarian cancer due to BRCA1 and BRCA2 mutations...
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinomaDavid M Hyman
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E 66th Street, New York, NY 10065, USA
Gynecol Oncol 126:224-8. 2012..BRCA-associated and sporadic ovarian cancers have different pathologic and clinical features. Our goal was to determine if BRCA mutation status is an independent predictor of residual tumor volume following primary surgical cytoreduction...
Genome-wide association studies of cancerZsofia K Stadler
Clinical Genetics Service andthe Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, NY, NY 10021, USA
J Clin Oncol 28:4255-67. 2010..To date, however, the clinical utility of GWAS-derived risk markers remains limited...
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutationNoah D Kauff
Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
N Engl J Med 346:1609-15. 2002..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancerDavid M Hyman
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Cancer 118:3703-9. 2012..The objective of the current study was to examine whether BRCA1-associated and BRCA2-associated ovarian cancers were associated with different outcomes...
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancerZsofia K Stadler
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 118:493-9. 2012..Breast-pancreas cancer families with BRCA1 mutations have also been observed. The influence of a family history (FH) of PC on BRCA mutation prevalence in patients with breast cancer (BC) is unknown...
Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2Deborah Goldfrank
Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Epidemiol Biomarkers Prev 15:2311-3. 2006..08; P = 0.03). These findings indicate that screening mammography is unlikely to be associated with a large increase in breast cancer risk in this population...
Hereditary ovarian cancer in Ashkenazi JewsLuis Robles-Díaz
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Fam Cancer 3:259-64. 2004..Ovarian cancer in Ashkenazi kindreds has served as a model for the study of the histopathology of inherited ovarian cancers as well as for the study of risk reduction and screening among all women at inherited risk of ovarian cancer...
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of lifeMartee L Hensley
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1278 York Avenue, New York, NY 10021 6094, USA
Gynecol Oncol 89:440-6. 2003..We sought to determine whether anxiety, depression, perception of ovarian cancer risk, and false-positive test frequency differed between high-risk premenopausal and postmenopausal women initiating ovarian cancer screening...
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutationsNoah D Kauff
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 97:1601-8. 2003..This finding suggests that hereditary breast carcinoma has a preinvasive phase that may be detectable with aggressive surveillance...
Screening and prevention of hereditary gynecologic cancersSiobhan M Kehoe
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 34:406-10. 2007..Additionally, we outline ongoing questions and areas for future research...
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancersDavid M Hyman
Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Gynecol Oncol 123:196-9. 2011..To evaluate the efficacy of topoisomerase I inhibitor, topotecan, in patients with recurrent BRCA+ versus BRCA- ovarian, fallopian tube, and primary peritoneal carcinomas...
Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgeryChristopher S Awtrey
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Gynecol Oncol 99:720-5. 2005..01]). CONCLUSIONS: Laparoscopic RRSO is safe and feasible in patients who have undergone a prior TRAM flap reconstruction...
Genome-wide association studies of cancer predispositionZsofia K Stadler
Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hematol Oncol Clin North Am 24:973-96. 2010..Studies involving more heterogeneous populations, determination of the causal variants, and functional studies are now necessary to further elucidate the potential biologic and clinical significance of the observed associations...
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancersKenneth Offit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:3813-9. 2002..We next sought to determine the frequency of ATM variants in patients with Hodgkin's lymphoma, regardless of coexisting BC, compared with healthy volunteers...
Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalitiesKaruna Garg
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Am J Surg Pathol 33:925-33. 2009..Tumor morphology (TM-MMR) along with IHC-MMR enhances the detection of EC patients at risk of HNPCC...
Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?Noah D Kauff
Gynecol Oncol 93:277-9. 2004
The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomyRam Eitan
Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
Gynecol Oncol 102:315-8. 2006..No patients with mesothelial atypia went on to develop peritoneal carcinoma. The link between mesothelial atypia and mutations in BRCA1/2 and the need to perform peritoneal washings in this setting are both yet to be determined...
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositionsJohnathan M Lancaster
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Gynecol Oncol 107:159-62. 2007..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome...
Reducing the risk of gynecologic cancer in the Lynch syndromeKenneth Offit
N Engl J Med 354:293-5. 2006
Does a BRCA mutation plus tamoxifen equal hysterectomy?Karen H Lu
Gynecol Oncol 104:3-4. 2007
Modeling genetic risk of breast cancerNoah D Kauff
JAMA 297:2637-9. 2007
Research Grants
- Structural, Computational and Epidemiologic Analyses of*Noah Kauff; Fiscal Year: 2006..abstract_text> ..
